Immunome, Inc. (IMNM) AI Stock Analysis

Immunome, Inc. is a biopharmaceutical company headquartered in Exton, Pennsylvania, focused on discovering and developing antibody therapeutics for oncology and infectious diseases. Established in 2006, the firm utilizes an antibody discovery platform to address immune evasion mechanisms and critical health conditions. Its lead oncology program features IMM-ONC-01, an antibody designed to target IL-38, a tumor-derived immune checkpoint. In infectious diseases, Immunome is developing IMM-BCP-01, an antibody cocktail product candidate designed to combat SARS-CoV-2 infections and address COVID-19. The company operates from its Exton research facilities with 247 employees.

Immunome reported revenue of $6.6M in FY2022, rising 111.5% to $14.0M in FY2023 before falling 35.5% to $9.0M in FY2024 and falling 23.2% to $6.9M in FY2025. This yields a three-year revenue compound annual growth rate of 1.6%. Research and development expenses increased from $23.3M in FY2022 to $174.3M in FY2025. Consequently, operating margin worsened to -3084.8% in FY2025, and net income was -$212.4M, or -$2.43 per share. For the trailing twelve months ended June 30, 2026, revenue stood at $0, with quarterly revenue falling 100.0% year-over-year and diluted EPS at -$2.52.

As of June 30, 2026, Immunome held $520.0M in cash and short-term investments against total debt of $4.6M, resulting in net cash of $515.4M. Shareholders' equity was $525.1M and total assets stood at $565.4M. Its liquidity profile shows a current ratio of 15.08 and a debt-to-equity ratio of 0.01. In FY2025, capital expenditures were $9.7M, operating cash flow was -$190.9M, and free cash flow was -$200.6M. Immunome has funded development primarily through equity issuance, with its share count increasing 849.1% over the past 5 years.

At a closing price of $16.47 on October 16, 2026, Immunome had a market capitalization of $1.94B and an enterprise value of $2.24B. The stock trades at a price-to-sales ratio of 791.8x and an enterprise value-to-revenue ratio of 580.3x, compared to a median price-to-sales multiple of 4.1x for the median of its US-listed Healthcare peers. Its price-to-book ratio is 5.2x. Over the past year, IMNM shares declined 0.1%, lagging the 16.8% return of the S&P 500 benchmark ETF (SPY). Over five years, the stock returned -6.5% compared to an 83.0% gain for SPY.

Wall Street coverage on Immunome consists of 12 Strong Buy ratings, 3 Buy ratings, and 1 Hold rating, with no Sell or Strong Sell ratings. The mean price target is $35.19, representing an upside of 113.6% over the last close of $16.47. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$2.29 and revenue of $266,670. For the following fiscal year, 13 analysts project revenue of $50.4M and an EPS of -$2.48. Over the last four quarters, the company beat EPS estimates 1 time. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Immunome, Inc. (IMNM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IMNM income statement, IMNM balance sheet, IMNM key metrics, IMNM analyst forecast, IMNM chart. See the IMNM stock overview for the latest quote and news.